IMMUNO-BIOLOGICAL LABORATORIES CO chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 72.80
Dividend & YieldN/A¥ (N/A)
Beta 0.29
Market capitalization 3.42B
Operating cash flow N/A
ESG Scores unknown

Company description

Immuno-Biological Laboratories Co., Ltd. researches, develops, manufactures, and supplies various immunological research reagents worldwide. It offers a range of antibodies and ELISA kits that are used for research and development in the fields of cancers and Alzheimer's disease, as well as lifestyle diseases, such as diabetes. The company also provides contract services to pharmaceutical firms and manufacturers of diagnostic products; and supplies antibodies for in-vitro diagnostic products, as well as licenses antibody drugs. In addition, it offers LipoTEST, a support testing services for animal medical care; LipoSEARCH lipid profiling and analyzing services; customized biomarker testing services for lifestyle related diseases; and other services, which include drug development and research support services. Further, the company develops Neosilk-Human Collagen I from transgenic silkworms for various cosmetic products; and proteins from transgenic silkworms for use in various drugs. Its antibodies serve pharmaceutical firms, universities, and laboratories in hospitals, and testing centers. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities 6M -24M -22M -1M
Total Cashflows From Investing Activities -593M 10M -17M -155M
Net Borrowings -124M -385M -216M 143M
Total Cash From Financing Activities -126M 81M -216M 143M
Change To Operating Activities -23M -28M 44M -2M
Issuance Of Stock 467M 467M
Net Income -167M -668M -318M -258M
Change In Cash -959M -517M -422M -102M
Effect Of Exchange Rate 4M 4M 4M 1M
Total Cash From Operating Activities -243M -608M -194M -93M
Depreciation
Change To Account Receivables -5M 37M -27M 25M
Other Cashflows From Financing Activities -2M -1M
Change To Netincome 2M 72M 88M 150M
Capital Expenditures -13M -13M -13M

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development 236M 318M 267M 188M
Income Before Tax -164M -659M -310M -250M
Net Income -167M -668M -318M -258M
Selling General Administrative 397M 494M 320M 310M
Gross Profit 460M 216M 346M 376M
Ebit -173M -596M -241M -122M
Operating Income -173M -596M -241M -122M
Interest Expense -1M
Income Tax Expense 3M 9M 8M 8M
Total Revenue 781M 576M 602M 647M
Cost Of Revenue 321M 360M 256M 271M
Total Other Income ExpenseNet 9M -63M -69M -128M
Net Income From Continuing Ops -167M -668M -318M -258M
Net Income Applicable To Common Shares -167M -668M -318M -258M

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 843M 424M 209M 337M
Total Stockholder Equity 2.15B 1.95B 1.63B 1.37B
Other Current Liabilities 143M 109M 91M 79M
Total Assets 2.99B 2.37B 1.84B 1.71B
Common Stock 2.79B 3.03B 3.03B 3.03B
Other Current Assets 23M 44M 12M 122M
Retained Earnings -2.47B -3.14B -3.46B -3.72B
Treasury Stock 3M -2M
Cash 1.54B 1.03B 604M 508M
Total Current Liabilities 550M 397M 145M 228M
Other Stockholder Equity 4M 1M 1M -1M
Property, Plant, and Equipment 114M 113M 127M 120M
Total Current Assets 2.11B 1.59B 1.12B 1.13B
Net Tangible Assets 2.15B 1.95B 1.63B 1.37B
Net Receivables 208M 171M 198M 173M
Accounts Payable 4M 4M 7M 3M


Insider Transactions

Here are the insider transactions of stock shares related to IMMUNO-BIOLOGICAL LABORATORIES CO:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to IMMUNO-BIOLOGICAL LABORATORIES CO. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on IMMUNO-BIOLOGICAL LABORATORIES CO

Here is the result of two systematic investment strategies applied to IMMUNO-BIOLOGICAL LABORATORIES CO. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows the equity curve of the two systematic investment strategies applied to IMMUNO-BIOLOGICAL LABORATORIES CO:

IMMUNO-BIOLOGICAL LABORATORIES CO automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -27.29% on the backtest period.

Performance at glance

Performance

-27.29 %

Latent gain

-2049.0 ¥

Invested capital

7509.0 ¥

Annualized return

-6.5 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on IMMUNO-BIOLOGICAL LABORATORIES CO

This is the result of two momentum investment strategies applied to IMMUNO-BIOLOGICAL LABORATORIES CO. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows all the entries opened by the momentum investment system on IMMUNO-BIOLOGICAL LABORATORIES CO:

IMMUNO-BIOLOGICAL LABORATORIES CO momentum entries
  • The first momentum investment strategy would give -33.26% of return on IMMUNO-BIOLOGICAL LABORATORIES CO. That represents -3265.0¥ of latent gain with 9817.0¥ of employed capital.
  • The second momentum investment strategy would give -26.23% of return on IMMUNO-BIOLOGICAL LABORATORIES CO. That represents -2524.0¥ of latent gain with 9622.0¥ of employed capital.
Performance at glance (1Q Momentum)

Performance

-33.26 %

Latent gain

-3265.0 ¥

Invested capital

9817.0 ¥

Annualized return

-8.08 %
Performance at glance (2Q Momentum)

Performance

-26.23 %

Latent gain

-2524.0 ¥

Invested capital

9622.0 ¥

Annualized return

-7.05 %

Momentum equity curve on IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows the equity curve of the two momentum strategies applied to IMMUNO-BIOLOGICAL LABORATORIES CO:

IMMUNO-BIOLOGICAL LABORATORIES CO momentum equity

Note: the dividends potentially given by IMMUNO-BIOLOGICAL LABORATORIES CO are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows the employed capital evolution of the two momentum strategies on IMMUNO-BIOLOGICAL LABORATORIES CO since the beginning:

IMMUNO-BIOLOGICAL LABORATORIES CO

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250¥, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000¥.


Buy the dip strategy result on IMMUNO-BIOLOGICAL LABORATORIES CO

Buy the dip entry openings on IMMUNO-BIOLOGICAL LABORATORIES CO

IMMUNO-BIOLOGICAL LABORATORIES CO

The performance achieved by the robo-advisor on IMMUNO-BIOLOGICAL LABORATORIES CO is -17.77%. That represents -118.0$ of latent gain with 664.0¥ of employed capital. The following chart shows IMMUNO-BIOLOGICAL LABORATORIES CO stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of IMMUNO-BIOLOGICAL LABORATORIES CO, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-17.77 %

Latent gain

-118.0 ¥

Invested capital

664.0 ¥

Annualized return

-8.08 %

Equity curve of the strategy applied to IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows the result of the investment strategy applied to IMMUNO-BIOLOGICAL LABORATORIES CO:

IMMUNO-BIOLOGICAL LABORATORIES CO

Note: the dividends potentially given by IMMUNO-BIOLOGICAL LABORATORIES CO are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows the employed capital evolution since the beginning of the investment strategy on IMMUNO-BIOLOGICAL LABORATORIES CO:

IMMUNO-BIOLOGICAL LABORATORIES CO

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on IMMUNO-BIOLOGICAL LABORATORIES CO

In this section, I will compare the three previous investment strategies applied to IMMUNO-BIOLOGICAL LABORATORIES CO.

Equity curve comparison on IMMUNO-BIOLOGICAL LABORATORIES CO

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

IMMUNO-BIOLOGICAL LABORATORIES CO investment strategy comparison

Employed capital comparison on IMMUNO-BIOLOGICAL LABORATORIES CO

IMMUNO-BIOLOGICAL LABORATORIES CO investment comparison

Performance comparison on IMMUNO-BIOLOGICAL LABORATORIES CO

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -27.29% -2049.0¥ 7509.0¥ -6.5%
Momentum 1 quarter -33.26% -3265.0¥ 9817.0¥ -8.4%
Momentum 2 quarters -26.23% -2524.0¥ 9622.0¥ -7.05%
Non-directional -17.77% -118.0¥ 664.0¥ -8.08%
Annualized return comparison

Automatic investment

-6.5 %

Momentum 1Q

-7.05 %

Momentum 2Q

-7.05 %

Non-directional

-8.08 %

Correlated stocks

Here are the most positively and negatively correlated stocks with IMMUNO-BIOLOGICAL LABORATORIES CO:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between IMMUNO-BIOLOGICAL LABORATORIES CO and the other stocks. There may be false positives or some missing correlated stocks. If the price of IMMUNO-BIOLOGICAL LABORATORIES CO does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name IMMUNO-BIOLOGICAL LABORATORIES CO
Country Japan
City Fujioka
Address Fujioka Laboratory
Phone 81 2 7422 2889
Website www.ibl-japan.co.jp
FullTime employees 63
Industry Biotechnology
Sector Healthcare
Exchange XTKS
Ticker 4570.XTKS
Market www.jpx.co.jp

IMMUNO-BIOLOGICAL LABORATORIES CO ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown